1.1Topical nerve growth factor
A sterile aqueous drop delivers the protein to the ocular surface. The protein activates its receptor on corneal sensory neurons and supports epithelial healing in eyes with impaired corneal innervation.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A sterile aqueous drop delivers the protein to the ocular surface. The protein activates its receptor on corneal sensory neurons and supports epithelial healing in eyes with impaired corneal innervation.
Blood from the subject clots, and centrifugation separates the serum. Sterile saline dilutes the serum for topical delivery of proteins and growth factors that support epithelial cell migration and attachment.
A sterile aqueous solution delivers dissolved sodium hyaluronate from a single-dose container. The polymer retains water and increases tear film viscosity, reducing friction between the eyelid and the ocular surface during blinking.
A retaining ring holds a cryopreserved amniotic membrane against the ocular surface. The membrane covers the defect, reduces direct contact with the blinking eyelid, and provides a substrate that supports epithelial migration.
A plug sized to the lower lacrimal punctum occupies the opening, and a flange rests at the lid margin. The plug restricts drainage into the nasolacrimal system and increases tear residence time on the ocular surface.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary clinic uses a sterile ophthalmic formulation containing 7,8-dihydroxyflavone to administer the compound to a dog with a persistent corneal epithelial defect. A clinician examines the cornea with fluorescein and records the dimensions of the stained area. The clinician instills the formulation into the lower conjunctival sac and measures the stained area again at follow-up visits.
An ophthalmic formulation for neurotrophic keratitis uses recombinant human nerve growth factor in place of 7,8-dihydroxyflavone. The protein is dissolved in a sterile, buffered aqueous vehicle and packaged in single-use containers under refrigerated storage. A dropper delivers the formulation into the lower conjunctival sac, where the fluid mixes with the tear film and spreads across the cornea.
A sterile ophthalmic formulation uses hydroxypropyl beta-cyclodextrin in place of an organic cosolvent to carry 7,8-dihydroxyflavone in water. The cyclodextrin is dissolved in buffered water and mixed with the compound to form a soluble inclusion complex. The resulting solution is sterile-filtered and filled into single-use droppers for topical instillation.
Two calibrated ophthalmic dispensers deliver the same concentration of 7,8-dihydroxyflavone in nominal drop volumes of 10 and 30 microliters. Each dispenser delivers one drop per trial onto a curved corneal model coated with artificial tear fluid. An absorbent collector below the model captures runoff, and gravimetric measurements compare the fraction of each drop retained after 30 seconds.
A rigid gas-permeable scleral lens vaults the cornea and holds a fluid reservoir between its back surface and the ocular surface. Before insertion, the lens bowl is filled with a sterile, preservative-free ophthalmic formulation containing 7,8-dihydroxyflavone. The lens is seated on the sclera, and the reservoir holds the formulation against the cornea until the lens is removed.
A slit-lamp camera captures fluorescein images before the first administration of 7,8-dihydroxyflavone and at follow-up examinations. Software uses a calibration image to convert pixel counts to square millimeters and segments the stained defect boundary within the corneal outline. The software stores each image, the measured defect area, and the time since administration so that a clinician can review the change over time.
A preservative-free, buffered aqueous vehicle carries micronized 7,8-dihydroxyflavone, with hypromellose increasing viscosity to slow settling. The contents are mixed before a single-dose dropper delivers the suspension into the lower conjunctival sac.
A sterile ophthalmic ointment disperses micronized 7,8-dihydroxyflavone in a white petrolatum and mineral oil base. A narrow ribbon applied inside the lower eyelid spreads across the ocular surface with blinking.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The methods include administering to a subject a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof.A · US 9,895,344 B2 · ¶ 6
The present invention relates to methods of restoring brain development in individuals with Down syndrome with a flavone derivative, 7,8-dihydroxyflavone (7,8-DHF).B · US 10,945,989 B2 · abstract
An empty cell means only that no passage was reproduced there.
Preclinical evidence indicates that BDNF might be useful as a therapeutic agent for various neurologic and neuropsychiatric disorders; however, the in vivo instability of such a peptide therapy limits its usefulness.A · US 9,895,344 B2 · ¶ 4
A further method of promoting neuroprotection in a subject is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.A · US 9,895,344 B2 · ¶ 6
The molecular mechanisms underlying brain development alterations are likely to be manifold, due to the complexity of gene imbalance in DS, and no therapies currently exist for the rescue of neurocognitive impairment in DS.B · US 10,945,989 B2 · ¶ 4
The present invention relates to methods of restoring brain development in individuals with Down syndrome.B · US 10,945,989 B2 · ¶ 2
patent.fyi, US 2026/0355146 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355146/, SHA-256 ba360e8016267c83f61c197eb93cb8a77172d707a0b10cf9b2d2d7c1136a68bb